AbbVie Loses Chancery Fight For Takeda Contract Injunction

By Jeff Montgomery (September 8, 2021, 3:48 PM EDT) -- AbbVie Endocrine Inc. has lost a bid for a Delaware Chancery Court injunction that would bind Japan's Takeda Pharmaceutical Co. Ltd. to North American delivery targets for a globally important drug as part of an eventual contract breach award, despite AbbVie's claims of irreparable harm risks....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!